|Articles|November 1, 2001

New Directions in the Treatment and Prevention of Deep Vein Thrombosis
Volume 7
Issue 17 Suppl

Prophylaxis Strategies for Patients with Acute Venous Thromboembolism

Author(s)Victor F. Tapson, MD

Download PDF: Prophylaxis Strategies for Patients with Acute Venous Thromboembolism

Articles in this issue

over 24 years ago

Article

Participating Faculty

over 24 years ago

Article

Introduction

over 24 years ago

Article

Treatment of Deep Vein Thrombosis Using Low-Molecular-Weight Heparins

over 24 years ago

Article

Economic Issues in the Treatment and Prevention of Deep Vein Thrombosis From a Managed Care Perspective

over 24 years ago

Article

The Use of Pharmacoeconomics in Formulary Development: Can This Improve the Way Deep Vein Thrombosis is Treated?

over 24 years ago

Article

Interview

over 24 years ago

Article

Continuing Medical Education Quiz

over 24 years ago

Article

Literature Review

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

The Timing and Characteristics of Supplemental Indications for Medicines

ByYingying Zhu, PhD,Claire H. Brennan, BA,Haijun Tian, PhD,Josephine N. Tran, PharmD, MS,Peter J. Neumann, ScD,James D. Chambers, PhD,Pei-Jung Lin, PhD,Meng Li, PhD

July 6th 2026

State Medicaid Budgetary Implications of New Cancers

ByAmanda C. Chen, PhD,Anuraag R. Kansal, PhD,David C. Grabowski, PhD

July 2nd 2026

Blood Pressure Control Among Adherent vs Nonadherent Medicare Patients With Hypertension

ByKaitlyn T. Haas, PharmD,Joseph J. Saseen, PharmD, BCPS, BCACP,Oliver Titus, MS,Nathan Lamberton, PharmD, BCACP,Lisa M. Schilling, MD, MSPH,Keri N. Hogan, PharmD, BCACP,Alison Marks, BA,Sarah J. Billups, PharmD, BCPS

July 1st 2026

The Effect of Medicaid Reimbursement for Psychiatrists on the Health Care Burden of Serious Mental Illness

ByOnur Baser, PhD, MS,Heidi C. Waters, PhD,Nehir Yapar, BS,Gabriela Samayoa, MD, MPH,Xue Han, PhD,Deborah Freedman, MBA,Lauren Isenman, MPH,Rashmi Patel, MD, PhD

June 12th 2026

Association of Travel Nursing With Quality Outcomes in Hospitalized Patients

ByJason Bartock, MD,Adam Green, MD,Raquel Nahra, MD,Amy Bordogna, MD,Amir Davoodi, MD,Jean-Sebastien Rachoin, MD

June 11th 2026

Prophylaxis Strategies for Patients with Acute Venous Thromboembolism

Articles in this issue

Related Content

The Timing and Characteristics of Supplemental Indications for Medicines

State Medicaid Budgetary Implications of New Cancers

Blood Pressure Control Among Adherent vs Nonadherent Medicare Patients With Hypertension

The Effect of Medicaid Reimbursement for Psychiatrists on the Health Care Burden of Serious Mental Illness

Association of Travel Nursing With Quality Outcomes in Hospitalized Patients

Trending on AJMC

Medicare GLP-1 Bridge Launches, but Who Actually Qualifies?

FDA Advisory Committee Supports Moderna mRNA Flu Vaccine Review

Online GLP-1 Sellers Often Skip Clinician Oversight

Early Treatment Succeeds in CRC With Next-Generation KRAS Inhibitor Calderasib Plus Cetuximab Combo

Real-World Data Show MASH Progresses Faster Than Trials Suggest

Access, Affordability, & Accountability: A New Era in Oncology Reimbursement

Prophylaxis Strategies for Patients with Acute Venous Thromboembolism

Articles in this issue

Related Content

The Timing and Characteristics of Supplemental Indications for Medicines

State Medicaid Budgetary Implications of New Cancers

Blood Pressure Control Among Adherent vs Nonadherent Medicare Patients With Hypertension

The Effect of Medicaid Reimbursement for Psychiatrists on the Health Care Burden of Serious Mental Illness

Association of Travel Nursing With Quality Outcomes in Hospitalized Patients

Trending on AJMC

Medicare GLP-1 Bridge Launches, but Who Actually Qualifies?

FDA Advisory Committee Supports Moderna mRNA Flu Vaccine Review

Online GLP-1 Sellers Often Skip Clinician Oversight

Early Treatment Succeeds in CRC With Next-Generation KRAS Inhibitor Calderasib Plus Cetuximab Combo

Real-World Data Show MASH Progresses Faster Than Trials Suggest